HER2 is a valuable tumor marker for therapeutic decision-making for patients with breast cancer. There are several possible uses of HER2 testing in clinical decisions. Because HER2-positive breast cancers tend to be more aggressive, positivity is associated with a worse prognosis. HER2-positive patients respond well to certain chemotherapies, such as Herceptin®(trastuzumab).
